Novo, a $20bn quasi-corporate venturing investment company wholly owned by the Novo Nordisk Foundation, is leading a $130m round for Symphogen.
Symphogen, a Denmark-based developer of antibody therapeutics to treat cancer and disease, has raised €100m ($130m) in Europe’s largest medical venture round and broadly double its previous equity funding.
Novo, a $20bn quasi-corporate venturing investment company wholly owned by the Novo Nordisk Foundation, led the round, and was joined by local pension fund PKA as a new investor and venture capital firm Essex Woodlands Health Ventures.
Essex Woodlands, which previously led Symphogen’s €33m round in February 2009, and Novo…
